期刊文献+

3种不同止吐方案防治顺铂所致呕吐的成本-效果分析 被引量:4

The Cost-Effectiveness Analysis of Three Preventing Schemes for Cisplatin-Induced Vomiting
下载PDF
导出
摘要 目的比较3种5-羟色胺3受体拮抗剂治疗顺铂所致呕吐的经济学效果。方法 3组患者顺铂化疗期间分别予以帕洛诺司琼(A组)、阿扎司琼(B组)及格拉司琼(C组),观察对于呕吐反应防治的有效率,并采用药物经济学方法进行成本-效果分析。结果 A、B、C组对于急性呕吐的有效率分别为85.0%、80.4%、78.6%,比较差异无统计学意义(P>0.05);成本分别为925.2元、349.5元及276.7元,其中C组所需成本最低(P均<0.05)。但对于延迟性呕吐的有效率,A组明显高于其他2组(P均<0.05),成本-效果分析也以A组最佳。结论对于顺铂所致急性呕吐,格拉司琼是较为合理方案;而对于延迟性呕吐,帕洛诺司琼更优。 Objective To evaluate the cost-effectiveness of three 5-hydroxy tryptamine 3 (5-HT3 ) receptors suppressant for cisplatin-induced vomiting. Methods All the patients received cisplatin chemotherapy were randomly divided into three groups according to the preventing schemes: group A (treated with palonosetron) ,group B (treated with azasetron) and group C (treated with granisetron). The data were analyzed by using pharmacoeconomic cost-effectiveness analysis. Results The response rate of prevention of acute vomit were 85.0% ,80.4% ,78.6% in group A, B, C ( P 〉 0.05 ) ; the costs in group A, B, C were 925.2,349.5 and 276.7 yuan ( P 〈 0.05 ) ,the costs in group C was the lowest. While palonosetron ( group A) was superior to azasetron ( group B ) and granisetron ( group C) in the prevention of chronic vomit ( P 〈 0.05 ), the result of cost-effectiveness analysis showed that group A was the best. Conclusion For the prevention of acute vomit induced by cisplatin, granisetron is the most economical one; while for the chronic vomit,palonosetron is the most.
出处 《肿瘤基础与临床》 2012年第5期414-417,共4页 journal of basic and clinical oncology
关键词 成本-效果分析 顺铂 呕吐 5-羟色胺 cost-effectiveness analysis cisplatin vomiting 5-hydroxy tryptamine
  • 相关文献

参考文献11

  • 1Wiser W,Berger A.Practical management of chemotherapy-induced nausea and vomiting[J].Oncology(Williston Park),2005,19(5):637-645.
  • 2姜松龄,李心忠.多西他赛联合顺铂治疗晚期非小细胞肺癌的临床观察[J].肿瘤基础与临床,2011,24(1):19-20. 被引量:30
  • 3周明祥,季进锋,王建红,钱云.DF方案治疗晚期胃癌的近期疗效观察[J].肿瘤基础与临床,2011,24(4):300-302. 被引量:4
  • 4Botrel TE,Clark OA,Clark L,et al.Efficacy of palonosetron (PAL) compared to other serotonin inhibitors (5-HT3R) in preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately or highly emetogenic (MoHE) treatment:systematic review and meta-analysis[J].Support Care Cancer,2011,19(6):823-832.
  • 5Likun Z,Xiang J,Yi B,et al.A systematic review and meta-analysis of intravenous palonosetron in the prevention of chemotherapy-induced nausea and vomiting in adults[J].Oncologist,2011,16(2):207-216.
  • 6Craver C,Gayle J,Balu S,et al.Palonosetron versus other 5-HT3 receptor antagonists for prevention of chemotherapy-induced nausea and vomiting in patients with hematologic malignancies treated with emetogenic chemotherapy in a hospital outpatient setting in the United States[J].J Med Econ,2011,14(3):341-349.
  • 7Aapro MS,Grunberg SM,Manikhas GM,et al.A phase Ⅲ,double-blind,randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy[J].Ann Oncol,2006,17(9):1441-1449.
  • 8Tian W,Wang Z,Zhou J,et al.Randomized,double-blind,crossover study of palonosetron compared with granisetron for the prevention of chemotherapy-induced nausea and vomiting in a Chinese population[J].Med Oncol,2011,28(1):71-78.
  • 9Oge A,Alki(s) N,Oge O,et al.Comparison of granisetron,ondansetron and tropisetron for control of vomiting and nausea induced by cisplatin[J].J Chemother,2000,12(1):105-108.
  • 10Eisenberg P,Figueroa-Vadillo J,Zamora R,et al.Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron,a pharmacologically novel 5-HT3 receptor antagonist:results of a phase Ⅲ,single-dose trial versus dolasetron[J].Cancer,2003,98(11):2473-2482.

二级参考文献9

  • 1黄美欧,姚红莹,刘涛.多西紫杉醇联合顺铂治疗非小细胞肺癌的临床观察[J].实用医技杂志,2006,13(1):67-68. 被引量:5
  • 2朱韧,倪健.多西他赛联合顺铂或卡铂治疗晚期非小细胞肺癌[J].中国癌症杂志,2006,16(4):320-322. 被引量:26
  • 3崔同建,刘振华,陈峥,张桂枫.晚期非小细胞肺癌4种化疗方案临床对照研究[J].肿瘤学杂志,2006,12(2):136-138. 被引量:22
  • 4Van Cutsem E,Moiseyenko VM,Tjulandin S,et al. Phase III study of docetaxel and cisplatin plus fiuorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group[J]. J Clin Oneol,2006,24(31):4991 - 4997.
  • 5孙燕,周际昌.临床肿瘤内科于册[M].3版.北京:人民卫生出版社,1996:197-198,214.
  • 6Murad AM, Petroianu A, Guimaraes RC, et al. Phase II Irial of the combination of paclitaxel and 5-fhiorouracil in the treatment of advanced gastric cancer: a novel, safe, and effective regimen [ J ]. Am J Clin Oncol,1999,22(6) :580 -586.
  • 7Hailer DG, Misset JL. Doeetaxel in advarw, ed gastric cancer[J]. Anticancer Drags, 2002,13 ( 5 ) :451 - 460.
  • 8Ferlini C,Scambia G,Distefano M,et al.Synergistic antiproliferative activity of tamoxifen and docetaxel on three oestrogen receptornegative cancer cell fines is mediated by the induction of apoptosis[J].Br J Cancer,1997,75(6):884 -891.
  • 9孙燕 周际昌.临床肿瘤内科手册[M].北京:人民卫生出版社,1996.138.

共引文献32

同被引文献133

引证文献4

二级引证文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部